North Carolina Product Liability Lawyer Blog

Articles Tagged with dupilumab

Dupixent Potentially Linked to Cancer: What You Need To Know

Published on: October 27, 2025 | By Clay Hodges

In 2017, the U.S. Food and Drug Administration (FDA) approved dupilumab (which goes by the brand name Dupixent) as a treatment for atopic dermatitis (commonly known as eczema). However, recent research has identified a possible link between Dupixent and cutaneous T-cell lymphoma (CTCL), a type of cancer. If you have taken (or are taking) Dupixent, you should be aware of this potential link and discuss the risks with your doctor.

An Overview of Dupixent

Regeneron Pharmaceuticals and Sanofi worked together to develop Dupixent. Dupixent is a monoclonal antibody, which means it’s a biologic, or medicine made from living organisms or parts of living organisms. It’s administered as an injection and is often used to treat moderate to severe cases of eczema where more topical treatments have been unsuccessful or aren’t possible. Dupixent is also used to treat:

Initial Consultation919-546-8788

★★★★★

I was involved in a case for the faulty hip replacements. Clay Hodges represented me. I can't say enough about how much he has helped me. Clay was able to win multiple settlements on my behalf with most of them being the maximum amount able to be awarded. Matt J.

★★★★★

Clay, thank you sir for making a disheartening experience at least palatable, you and your staff were honest, caring and understanding through the entire process of my wife’s hip replacements, while monetary settlements never make the pain and suffering end, it sometimes is the only way people can fight back to right a wrong. J. V.

★★★★★

We are absolutely pleased with how Clay Hodges handled my husband’s hip replacement claim. He always kept us informed of the progress. And, his work resulted in a settlement which we are extremely pleased. Thank you, Clay! Carol L. & Norm L.